{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:55:45Z","timestamp":1760061345587,"version":"build-2065373602"},"reference-count":22,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,5,21]],"date-time":"2017-05-21T00:00:00Z","timestamp":1495324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adrenocortical carcinoma (ACC) is an aggressive malignancy of the adrenal gland. Mitotane (<jats:italic>o<\/jats:italic>,<jats:italic>p'<\/jats:italic>\u2010DDD) is the most effective chemotherapy for ACC. According to the literature, mitotane plasma trough concentrations within 14\u201320\u2009mg L<jats:sup>\u22121<\/jats:sup> are correlated with a higher response rate with acceptable toxicity. Therapeutic drug monitoring (TDM) of mitotane is therefore recommended. The aim of this study was to propose a robust and simple method for mitotane quantification in plasma. The validation procedures were based on international guidelines. Sample preparation consisted of a single protein precipitation with methanol using 100\u2009\u03bcL of plasma. The supernatant was submitted to liquid chromatography coupled with ultra\u2010violet detection at 230\u2009nm. Mitotane retention time was 7.1\u2009min. The limit of detection was 0.1\u2009mg L<jats:sup>\u22121<\/jats:sup> and the limit of quantification was 0.78\u2009mg L<jats:sup>\u22121<\/jats:sup>. The assay demonstrated a linear range of 0.78\u201325\u2009mg L<jats:sup>\u22121<\/jats:sup> with correlation coefficients (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>) at 0.999. Inter\u2010 and intra\u2010assay precision was &lt;4.85%. Evaluation of accuracy showed a deviation &lt;13.69% from target concentration at each quality control level. This method proved easy and rapid to perform mitotane TDM and required a small volume of sample. It was successfully applied to routine TDM in our laboratory.<\/jats:p>","DOI":"10.1002\/bmc.3993","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T09:28:59Z","timestamp":1492853339000},"source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic drug monitoring of mitotane: Analytical assay and patient follow\u2010up"],"prefix":"10.1002","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-8908","authenticated-orcid":false,"given":"Catherine","family":"Feliu","sequence":"first","affiliation":[{"name":"Department of Pharmacology Centre Hospitalier Universitaire de Reims  Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoann","family":"Cazaubon","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Centre Hospitalier Universitaire de Reims  Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Guillemin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Centre Hospitalier Universitaire de Reims  Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Vautier","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Centre Hospitalier Universitaire de Reims  Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Oget","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Centre Hospitalier Universitaire de Reims  Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Millart","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Centre Hospitalier Universitaire de Reims  Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Gozalo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Centre Hospitalier Universitaire de Reims  Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoubir","family":"Djerada","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Centre Hospitalier Universitaire de Reims  Reims France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199906000-00020"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(87)80122-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0103"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.04.005"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.08.002"},{"key":"e_1_2_9_8_1","unstructured":"European Medicines Agency(n.d.\u2010a).Find medicine \u2010 Lysodren. Retrieved fromhttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000521\/human_med_000895.jsp&mid=WC0b01ac058001d124"},{"key":"e_1_2_9_9_1","unstructured":"European Medicines Agency(n.d.\u2010b). Retrieved fromhttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/includes\/document\/document_detail.jsp?webContentId=WC500109686%26mid=WC0b01ac058009a3dc"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02403.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.06.001"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2676"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-014-0189-7"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(87)90141-0"},{"issue":"2","key":"e_1_2_9_15_1","first-page":"125","article-title":"Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: Results of a long\u2010term follow\u2010up","volume":"5","author":"Kasperlik\u2010Zaluska A. A.","year":"2005","journal-title":"Journal of Experimental Therapeutics & Oncology"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0557"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.2696"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.014"},{"volume-title":"PDQ Cancer Information Summaries","year":"2002","author":"PDQ Adult Treatment Editorial Board","key":"e_1_2_9_19_1"},{"issue":"6","key":"e_1_2_9_20_1","first-page":"2234","article-title":"Low\u2010dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer","volume":"85","author":"Terzolo M.","year":"2000","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_9_21_1","unstructured":"US Food and Drug Administration(n.d.).Bioanalytical method validation. Retrieved fromhttp:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm368107.pdf"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(84)90033-6"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9291-7"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.3993","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.3993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T23:58:58Z","timestamp":1760054338000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.3993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,21]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/bmc.3993"],"URL":"https:\/\/doi.org\/10.1002\/bmc.3993","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"type":"print","value":"0269-3879"},{"type":"electronic","value":"1099-0801"}],"subject":[],"published":{"date-parts":[[2017,5,21]]},"article-number":"e3993"}}